Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

View/Open

Published version (122.2Kb)

Date

2017-04

ICR Author

Larkin, James

Marsden,

Author

Bowyer, S

Prithviraj, P

Lorigan, P

Larkin, J

McArthur, G

Atkinson, V

Millward, M

Khou, M

Diem, S

Ramanujam, S

Kong, B

Liniker, E

Guminski, A

Parente, P

Andrews, MC

Parakh, S

Cebon, J

Long, GV

Carlino, MS

Klein, O

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/636

DOI

https://doi.org/10.1038/bjc.2017.59

Collections

• Clinical Studies

Subject

Humans

Melanoma

Skin Neoplasms

CTLA-4 Antigen

Programmed Cell Death 1 Receptor

Ipilimumab

Research team

Melanoma and Kidney Cancer

Language

eng

License start date

2017-04

Citation

British journal of cancer, 2017, 116 (8), pp. e15 - ?